BI Asset Management Fondsmaeglerselskab A S Sells 101,457 Shares of ADMA Biologics Inc $ADMA

Key Points

• BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in ADMA Biologics by 92.2%, holding only 8,606 shares after selling 101,457 shares during the first quarter.
• Despite this reduction, other institutional investors have increased their positions, with New York State Teachers Retirement System boosting its stake by 96.2% and GAMMA Investing LLC raising theirs by 251.6%.
• ADMA Biologics reported a 13.8% year-over-year increase in revenue, totaling $121.98 million, and also exceeded analysts' EPS expectations by reporting $0.15 for the quarter.

BI Asset Management Fondsmaeglerselskab A S reduced its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 92.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 8,606 shares of the biotechnology company's stock after selling 101,457 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in ADMA Biologics were worth $171,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Northern Trust Corp grew its position in shares of ADMA Biologics by 0.8% in the first quarter. Northern Trust Corp now owns 2,594,756 shares of the biotechnology company's stock valued at $51,480,000 after purchasing an additional 19,681 shares during the last quarter. Brooklyn Investment Group grew its position in shares of ADMA Biologics by 28,655.6% in the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock valued at $51,000 after purchasing an additional 2,579 shares during the last quarter. Northwest & Ethical Investments L.P. acquired a new stake in shares of ADMA Biologics in the first quarter valued at about $190,000. Raymond James Financial Inc. grew its position in shares of ADMA Biologics by 18.7% in the first quarter. Raymond James Financial Inc. now owns 1,319,803 shares of the biotechnology company's stock valued at $26,186,000 after purchasing an additional 207,528 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D grew its position in shares of ADMA Biologics by 22.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 124,646 shares of the biotechnology company's stock valued at $2,473,000 after purchasing an additional 22,893 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ADMA. Raymond James Financial raised their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $27.67.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded up $0.13 during mid-day trading on Thursday, hitting $17.38. The company had a trading volume of 2,100,631 shares, compared to its average volume of 3,110,884. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The business's 50-day simple moving average is $17.79 and its 200-day simple moving average is $18.88. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The firm has a market cap of $4.15 billion, a P/E ratio of 20.21 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.13 earnings per share. As a group, analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares in the company, valued at $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 455,621 shares of company stock worth $9,461,633 over the last quarter. Company insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.